Therapy Areas: Infectious Diseases
Cortexyme's Approach to Addressing a Key Underlying Cause of Alzheimer's Detailed at Alzheimer's Association International Conference 2019
19 July 2019 - - US-based biopharmaceutical company Cortexyme, Inc. (NASDAQ: CRTX) has presented clinical data that supports its ongoing work to pioneer a novel, disease-modifying therapeutic approach...
US FDA grants approval to Merck's Recarbrio
19 July 2019 - The US Food and Drug Administration (FDA) has granted approval to United States-based Merck for its Recarbrio (imipenem, cilastatin and relebactam) intended to treat adults with complic...
FDA Approves US Merck's Recarbrio for the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Ltd. or No Alternative Treatment Options Are Available
18 July 2019 - - The US Food and Drug Administration has approved Recarbrio (imipenem, cilastatin, and relebactam) for injection, 1.25 grams, a new combination antibacterial, US-based pharmaceutical c...
FDA approves Recarbrio for complicated urinary tract and complicated intra-abdominal infections
18 July 2019 - The US Food and Drug Administration (FDA) on Wednesday cleared the marketing of the antibacterial drug Recarbrio (imipenem, cilastatin and relebactam), for adults with complicated urina...
Dicerna Receives Breakthrough Therapy Designation for DCR-PHXC for Treatment of Primary Hyperoxaluria Type 1
16 July 2019 - - The US Food and Drug Administration has granted a Breakthrough Therapy Designation to DCR-PHXC for the treatment of patients with primary hyperoxaluria type 1, US-based ribonucleic ac...
Recursion Pharmaceuticals Secures USD 121m in Series C Financing
16 July 2019 - - US-based biopharmaceutical company Recursion has closed a USD 121m Series C financing, the company said.
The round was led by Baillie Gifford's flagship investment trust, S...
Related Headlines

Silicon Therapeutics Expands Board by Naming Roger J. Pomerantz, MD, FACP as Chairman and Mark J. Gilbert, MD as a Director

CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

BioMarin Pharmaceutical names new director

Mobidiag Signs Exclusive Agreement with Pro Med Diagnostics for the Distribution of Amplidiag and Novodiag Diagnostic Solutions in Africa

Biological Dynamics Receives Grant Award Funding to Advance Point-of-Care Molecular Diagnostic Platform

Purdue Pharma appoints Dr Julie Ducharme as vice president and chief scientific officer

Enesi Pharma appoints Dr Steven Chatfield to Scientific Advisory Board

Enesi Pharma adds new Scientific Advisory Board member

Alexion Receives FDA Approval of Soliris for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are Anti-Aquaporin-4 Antibody Positive

Modag Launches Out of Stealth Mode with series A Financing of EUR 12 m to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy

Emergex Signs an R and D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot and Mouth Disease

Co-Diagnostics Names Durenard, Murphy to Board of Directors

Alnylam Touts Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery

Immunomic Therapeutics Promotes Heiland to Chief Scientific Officer

Tangen Biosciences Announces USD 9m series A Financing to Accelerate Development of Disruptive Molecular Diagnostic Platform